| 000 | 01545 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250515182951.0 | ||
| 264 | 0 | _c20091207 | |
| 008 | 200912s 0 0 eng d | ||
| 022 | _a0971-5916 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHanna, L E | |
| 245 | 0 | 0 |
_aIncomplete immunological recovery following anti-tuberculosis treatment in HIV-infected individuals with active tuberculosis. _h[electronic resource] |
| 260 |
_bThe Indian journal of medical research _cMay 2009 |
||
| 300 |
_a548-54 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcquired Immunodeficiency Syndrome _xcomplications |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aCD4-Positive T-Lymphocytes _ximmunology |
| 650 | 0 | 4 | _aCell Count |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 |
_aEthambutol _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIndia |
| 650 | 0 | 4 |
_aIsoniazid _xtherapeutic use |
| 650 | 0 | 4 |
_aNeopterin _xblood |
| 650 | 0 | 4 |
_aPyrazinamide _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor, Type I _xblood |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 |
_aTuberculosis _xcomplications |
| 650 | 0 | 4 |
_abeta 2-Microglobulin _xblood |
| 700 | 1 | _aNayak, Kaustuv | |
| 700 | 1 | _aSubramanyam, Sudha | |
| 700 | 1 | _aVenkatesan, Perumal | |
| 700 | 1 | _aNarayanan, P R | |
| 700 | 1 | _aSwaminathan, Soumya | |
| 773 | 0 |
_tThe Indian journal of medical research _gvol. 129 _gno. 5 _gp. 548-54 |
|
| 999 |
_c19081212 _d19081212 |
||